23 active not recruiting. 23 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Active not recruiting 23 |
| Phase 1 | 5 | Active not recruiting 5 |
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab - Pleural Mesothelioma | Phase 2 | Active not recruiting | Istituto Oncologico Veneto IRCCS | 41 | 2024-11-06 | 2026-01-13 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma Lenvatinib, Pemetrexed, Cisplatin/Carboplatin - Malignant Pleural Mesothelioma | Phase 2 | Active not recruiting | Hyogo Medical University | 25 | 2024-03-13 | 2026-09-16 |
| Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide - Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 31 | 2023-02-16 | 2026-10-20 |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Spartalizumab, Tislelizumab - MSI-H Colorectal Cancer, Melanoma | Phase 2 | Active not recruiting | SOLTI Breast Cancer Research Group | 184 | 2021-04-12 | 2025-03-21 |
| Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients Pembrolizumab, Lenvatinib - Mesotheliomas Pleural | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 58 | 2021-03-01 | 2024-11-05 |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma UV1 vaccine + leukine, ipilimumab, nivolumab - Cancer, Cancer, Lung | Phase 2 | Active not recruiting | Åslaug Helland | 118 | 2020-05-04 | 2024-02-29 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination - Gastric Cancer, Colorectal Cancer | Phase 2 | Active not recruiting | Udai Kammula | 20 | 2019-12-03 | 2026-06-01 |
| Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Abemaciclib - Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor | Phase 2 | Active not recruiting | University of Washington | 20 | 2019-10-31 | 2026-01-14 |
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Nivolumab Injection, Ipilimumab Injection - Mesothelioma | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2019-10-02 | 2026-06-05 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
| Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors CVM-1118 - Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor | Phase 2 | Active not recruiting | TaiRx, Inc. | 34 | 2018-12-15 | 2025-12-23 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab - Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2018-10-04 | 2026-10-15 |
| Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery Brentuximab Vedotin, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2017-04-05 | 2026-08-25 |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis - Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 133 | 2017-03-03 | 2026-09-14 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Cisplatin, Methoxyamine, Pemetrexed Disodium - Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2016-03-08 | 2026-07-31 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) pembrolizumab - Advanced Cancer, Anal Carcinoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 1609 | 2015-12-18 | 2025-09-22 |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab - Malignant Pleural Disease, Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 113 | 2015-05-01 | 2026-07-22 |
Showing 20 of 23. Sign in to see all of them.
Mesothelioma, Malignant (11) · Mesothelioma (9) · Adenoma, Islet Cell (5) · Cholangiocarcinoma (4) · Neuroendocrine Tumors (4) · Thyroid Neoplasms (4) · Anus Neoplasms (3) · Gastro-enteropancreatic neuroendocrine tumor (3) · Sarcoma (3) · Biliary Tract Neoplasms (2) · Carcinoma, Merkel Cell (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Ovarian Epithelial (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2)
Neoplasms by Histologic Type (23) · Neoplasms, Glandular and Epithelial (23) · Neoplasms (21) · Neoplasms by Site (21) · Neoplasms, Mesothelial (18) · Lung Diseases (14) · Respiratory Tract Diseases (14) · Respiratory Tract Neoplasms (14) · Thoracic Neoplasms (14) · Lung Neoplasms (12) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Pleural Neoplasms (11) · Adenocarcinoma (9)
pembrolizumab (6) · Cisplatin (4) · Nivolumab (4) · Pemetrexed (4) · Carboplatin (3) · Cyclophosphamide (3) · Ipilimumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Platinum (2) · fludarabine (2) · lenvatinib (2) · spartalizumab (2) · 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one (1) · Bevacizumab (1) · Brentuximab Vedotin (1)
Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Hyogo Medical University (1) · Instituto do Cancer do Estado de São Paulo (1) · Istituto Oncologico Veneto IRCCS (1) · MedImmune LLC (1) · Merck Sharp & Dohme LLC (1) · SOLTI Breast Cancer Research Group (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · TCR2 Therapeutics (1) · TaiRx, Inc. (1) · The Netherlands Cancer Institute (1) · Udai Kammula (1)
United States (15) · Canada (3) · Spain (3) · Australia (2) · Denmark (2) · Italy (2) · Netherlands (2) · Sweden (2) · Belgium (1) · Brazil (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Japan (1)
Anne S Tsao (2) · Aaron S Mansfield (1) · Alan L Ho, MD, PhD (1) · Camila MV Moniz, Doctor (1) · Charles Simone, MD (1) · David B. Zhen (1) · Giulia Pasello, MD (1) · Julie Brahmer, MD (1) · Kanwal P Raghav, MD (1) · Kozo Kuribayashi, MD, PhD (1) · Marianna Koczywas (1) · Roisin O'Cearbhaill, MD (1) · S Burgers, PhD (1)
PMID 27325859, PMID 28729154, PMID 30883000, PMID 30943124, PMID 31386610, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34059094, PMID 34990208, PMID 35045358, PMID 35114169, PMID 35361487, PMID 35389428, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36200668, PMID 36748723, PMID 37501016, PMID 37844598, PMID 38321811, PMID 39133306, PMID 39979665, PMID 40121391, PMID 40921804, PMID 41308680, PMID 41920388, PMID 42322509, PMID 42393461
2015 (1), U10CA032102 (1), U10CA180821 (1), U10CA180830 (1), U10CA180888 (1), UM1CA186686 (1), UM1CA186689 (1), UM1CA186705 (1), UM1CA186709 (1), UM1CA186717 (1), ZIABC011078 (1)